Simulations Plus (SLP)
(Delayed Data from NSDQ)
$12.80 USD
-0.22 (-1.69%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.79 -0.01 (-0.08%) 7:58 PM ET
5-Strong Sell of 5 5
D Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Simulations Plus, Inc. has a PEG ratio of 6.38 compared to the Computer - Software industry's PEG ratio of 2.77.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SLP 12.80 -0.22(-1.69%)
Will SLP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLP
Telefonica's Q2 Earnings Match, Top Line Misses Estimates & Slides Y/Y
ITRI Q2 Earnings Beat, Sales Lag, Stock Sinks 10% on Mixed Outlook
SLP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Blackbaud's Q2 Earnings Beat Estimates & Rise Y/Y, Stock Up
Fortive's Q2 Earnings Miss Estimates, Revenues Beat, Stock Down
Sensata's Q2 Earnings & Revenues Surpass Estimates, Decrease Y/Y
Other News for SLP
Conestoga Micro Cap Composite Q2 2025 Commentary
Conestoga Small Cap Composite Q2 2025 Commentary
Simulations Plus: Still Positioned For FDA In???Silico Trend Despite Near???Term Headwinds
Simulations Plus management to meet virtually with Craig-Hallum